Colistin use in patients with extreme renal function : From dialysis to augmented clearance by Aitullina, Aleksandra et al.
medicina
Article
Colistin Use in Patients with Extreme Renal Function:
From Dialysis to Augmented Clearance
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Abstract: Background and objectives: Colistin is used for the treatment of multidrug-resistant (MDR)
Gram-negative bacteria infection in critically ill patients. It is recommended to adjust the dose in
cases of renal impairment but not in cases of augmented renal clearance (ARC). The aim of this
study was to determine colistin use pattern in patients with different renal functional states. Materials
and Methods: Adult patients admitted to intensive care units of single Latvian hospitals in the years
2015–2017 with an MDR Gram-negative bacterial infection and at least 72 h colistin therapy were
included in this study. Data were collected retrospectively from medical notes. Colistin use pattern
and outcomes were analyzed in patients with different renal function prior to colistin therapy: normal,
ARC, impaired, and on renal replacement therapy (RRT). Results: 100 cases of colistin use met the
inclusion criteria. The study group was heterogeneous, and patients had different renal function states
prior to colistin therapy-from continuous RRT (18 cases) to ARC (16 cases). The standard colistin dose
of 9 million units (MU) daily was the most common dose among the patients. In many cases (43%),
colistin dose adjustment did not follow the recent recommendations of drug manufacturers-this
was mainly in patients with renal impairment prior to colistin therapy. Eighteen cases of colistin
acute kidney injury (AKI) were detected, mostly (10 cases) in patients with normal renal function
and without ARC prior to colistin therapy. No patients with colistin AKI needed RRT. Conclusions:
Colistin doses varied greatly among patients, and in patients with renal function impairment it was
commonly not in accordance with the summary of product characteristics (SPC). Patients with ARC
mostly received a standard colistin daily dose of 9 MU daily, but the cumulative dose had a tendency
to be higher and duration of colistin therapy was longer in comparison with other patient groups.
ARC’s role in the development of colistin nephrotoxicity is still unclear.
Keywords: colistin; augmented renal clearance; renal replacement therapy; Acinetobacter baumannii
1. Introduction
Colistin or polymyxin E is a cationic lipopeptide antibiotic that is administered intravenously as
a non-active pro-drug colistimethate sodium (CMS) that is hydrolyzed in vivo to become an active
substance [1]. This drug was discovered more than 60 years ago, but was not used for many years due
to the concern of nephrotoxicity and the availability of other less-toxic antibacterial agents. At present,
colistin is considered as a drug of last choice for the treatment of multidrug-resistant (MDR) systemic
Gram-negative infections in critically ill patients [2].
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CMS is eliminated mainly by the kidney, including renal tubular secretion, and colistin is
eliminated predominantly by non-renal pathways [3]. If CMS is cleared via the kidney too rapidly,
the systemic bioavailability of colistin could be reduced and that could theoretically lead to ineffective
antibacterial therapy [4]. The phenomenon of enhanced renal function is called augmented renal
clearance (ARC). There is a hypothesis that the development of ARC is related to the systemic
inflammatory response syndrome (SIRS) that is observed in patients without chronic organ damage
and with trauma, pancreatitis, burns, autoimmune disorders, major surgical procedures, ischemia,
or sepsis. The hemodynamic manifestations of SIRS include high cardiac output, and due to this,
enhanced renal blood flow. ARC is usually defined as the enhanced elimination of solute through the
kidney with renal clearance above the expected baseline. However, in this case, it is problematic to
define an ”expected or normal“ baseline value. The most widely accepted definition is a glomerular
filtration rate (GFR) above 130 mL/min, best measured by 8–24 h urine collection [5]. Due to the
potential risk of under-dosing renally cleared antibiotics, therapeutic drug monitoring (TDM) for these
drugs may be advisable in this group of patients [6].
Colistin is potentially nephrotoxic, but its renal toxicity is usually reversible [7]. Renal impairment
on baseline is not a contraindication for colistin administration, but dose adjustment is considered.
In the case of renal replacement therapy (RRT), there is no mechanism to return colistin from dialysate
back to blood. For this reason, colistin can be efficiently cleared during hemodialysis (HD) and therefore
the authors of the Garonzik et al. 2011 study suggest that dialysis is best conducted toward the end of
a CMS dosage interval [8]. Several years ago, there were no clear recommendations about colistin dose
adjustment in RRT [2]. At present, drug manufacturers suggest the use of a standard colistin dose of 9
million units (MU) per day in patients with normal renal function and on continuous RRT (CRRT).
This dose is reduced in cases of renal impairment (i.e., to 5.5–7.5 MU/day when creatinine clearance
(CrCl) <50–30 mL/min; to 4.5–5.5 MU/day when CrCl <30–10 mL/min; and to 3.5 MU/day when
CrCl <10 mL/min). Patients on intermittent HD (IHD) should receive 2.25 MU/day in non-HD days
and 3 MU/day after HD session in HD days [9]. In the case of CRRT, dosing recommendations could
also depend on different factors, such as the filter type used for dialysis. There are data suggesting
that some hyperadsorptive filters (e.g., AN69ST) could adsorb colistin, and thus higher doses might be
needed (e.g., 13.5 instead of 9 MU/day) [10].
The aim of this study was to determine the colistin use pattern in patients with different renal
functional states, including extreme renal functions, in a single clinical center in a Baltic country.
2. Material and Methods
The study setting was in intensive care units (ICUs) of a tertiary adult university hospital in
Riga, Latvia. The inclusion criteria were: adult patients, admitted to the ICU in the period of the
study (2015–2017), with bacteriologically documented carbapenem-resistant Gram-negative bacterial
infection, and systemic colistin therapy that started in the ICU. The exclusion criterion was colistin
use less than 72 h. Information about patients’ demographics, blood test results, clinical diagnoses,
duration of hospitalization and outcomes, colistin dosage regimens and duration of therapy, as well
as bacteriological test results and colistin minimal inhibitory concentratiion (MIC) were collected
retrospectively from medical notes. The colistin MIC breakpoint for Acinetobacter baumannii and
Pseudomonas aeruginosa is 2 mg/L according to the European Committee on Antimicrobial Susceptibility
Testing (EUCAST) data (v. 8.0; 01.01.2018). Patients who received a second intravenous colistin course
after a cured infectious episode were considered as two separates cases when analyzing colistin use
pattern and nephrotoxicity. On the other hand, in the demonstration of demographics and clinical data
of the study population, every patient was presented as a separate case regardless of the number of
colistin courses administered during hospitalization.
To reduce the risk of underestimation of renal function in cases of ARC, the assessment of baseline
renal function in non-dialyzed patients was based on the Chronic Kidney Disease Epidemiology
Collaboration (CKD-EPI) formula with a cut-off value for ARC of 108 mL/min/1.73 m2 [11].
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The patients were divided into four groups according to renal function state prior to colistin therapy:
the normal renal function group (defined as having a GFR of more than 50 mL/min/1.73 m2 and less
than 108 mL/min/1.73 m2), the ARC group (defined as having a GFR of more than 108 mL/min/1.73
m2), the renal function impairment group (defined as having GFR of less than 50 mL/min/1.73 m2 or
on IHD), and the CRRT group.
Colistin nephrotoxicity or colistin-induced acute kidney injury (AKI) was defined according
to Acute Kidney Injury Network criteria as increasing the baseline creatinine level more than 1.5
times over baseline after at least 48 h of colistin therapy. The first stage of AKI was considered
in cases of serum creatinine level increasing 1.5–1.9 times over baseline, the second stage in cases
of serum creatinine increasing 2.0–2.9 times over baseline, and the third stage in cases of serum
creatinine increasing more than 3.0 times over baseline [12]. The return to normal renal function
(GFR >50 mL/min) in patients with ARC was not considered as colistin AKI. If acute renal function
decline was observed in the day of patient death, these cases were excluded from further colistin AKI
analysis. The study was conducted in accordance with the Declaration of Helsinki, and the protocol
was approved by the Ethics Committee (48/05.10.2017).
Statistical Analysis
Continuous data were expressed in the form of medians and interquartile ranges (Q1; Q3).
Categorical data were expressed as counts and percentages. Normal distribution was assessed using
the Shapiro-Wilk test. Mann-Whitney U-tests, paired t-tests and Kruskal-Wallis tests were used for
data comparison amongst study populations. A p-value equal to or less than 0.05 was considered as
statistically significant. Statistical data analysis was performed by IBM SPSS, version 22 (Statistical
Package for the Social Sciences, Oshkosh, WI, USA).
3. Results
Ninety-seven medical histories met the inclusion criteria. Three patients received colistin therapy
twice with an interval between colistin courses of more than one month, so 100 cases of colistin use
were analyzed in total. Most of the included patients were men (65, or 67% of all cases). The median
age was 63 years. A. baumannii infection was the most common causative agent for systemic MDR
Gram-negative bacterial infection among patients in the study (98%), and the median hospitalization
days from bacteriological documentation of this infection was nine days. In all cases, MDR bacteria
were sensitive to colistin (the colistin MIC range for detected cases was 0.125–0.5 mg/L). MDR
Gram-negative infection was found mostly in trachea aspirate (78, or 80.4% of cases). In 17 (17.5%)
cases, it was isolated from the blood sample. The main data about patient demographics, clinical
diagnoses, and MDR nosocomial infection are summarized in Table 1.
Table 1. Demographics, clinical diagnoses, and MDR Gram-negative infection in study population
(n = 97).
Characteristics Values
Gender: men, n (%) 65 (67%)
Age, years
Median (Q1; Q3) 63.0 (51.0; 73.5)
Min–max 20.0–92.0
Duration of hospitalization, days
Median (Q1; Q3) 43.0 (26.5; 63.5)
Min–max 10.0–204.0
Patient death rate, n (%) 49.0 (50.5%)
Main clinical diagnoses groups, n (%):
Pulmonology (e.g., pneumonia, COPD) 28 (28.9%)
Neurology (e.g., subarachnoid hemorrhage) 21 (21.6%)
Cardiology (e.g., myocardial infarction, ACS) 19 (19.6%)
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Table 1. Cont.
Characteristics Values
Gastroenterology (e.g., severe acute pancreatitis) 8 (8.2%)
Other (e.g., cancer, acute kidney failure, trauma) 21 (21.6%)





Hospitalization days when MDR Gram-negative bacteria infection was diagnosed
Median (Q1; Q3) 9.0 (12.5; 21.0)
Min–max 3.0–78.0
Source of MDR Gram-negative bacteria infection
Trachea aspirate, n (%) 68 (68%)
Blood, n (%) 5 (5%)
Blood and trachea aspirate, n (%) 10 (10%)
Other material, including blood, n (%) 2 (2%)
Other material, without blood, n (%) 15 (15%)
Abbreviations: ACS: acute coronary syndrome; COPD: chronic obstructive lung disease; ICU: intensive care unit;
MDR: multidrug-resistant.
The study group was heterogeneous, and patients had different renal function states prior to
colistin therapy. In 43 cases, GFR was from 50–108 mL/min (normal renal function group), in 16
cases GFR was more than 108 mL/min (ARC group), in 23 cases GFR was less than 50 mL/min (renal
impairment group), and 18 patients were on CRRT on the day of starting of colistin therapy.
The most commonly used colistin regimen in all patient groups was 9 million units (MU) as
a loading dose (LD) followed by 3 MU every 8 h. Patients with renal function impairment had a
statistically higher probability of receiving smaller LD or of not receiving LD at all in comparison with
patients with normal renal function or ARC (p = 0.002). In addition, patients with renal impairment had
higher incidence of colistin under-dosing and over-dosing in comparison with other patient groups
(Pearson chi-sq. p = 0) (Figure 1).
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Patients in the ARC group were younger than patients with normal renal function or renal
impairment (p = 0.0003). They also received a higher cumulative colistin dose for a longer period of
time, but these two parameters did not reach statistical significance (Table 2).
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12 121 trachea aspirate ↓ 40 no alive 15
13 135 trachea aspirate S 21 no death 0
14 120 trachea aspirate S 24 no death 20
15 131 trachea aspirate S 12 AKI (last day ofcolistin use) death 0
16 136 trachea aspirate S 33 no alive 28
Abbreviations: AKI: acute kidney injury); Cr: serum creatinine; GFR: glomerular filtration rate; LD: loading dose.
* Colistin regimen: S-standard (3 million units (MU) three times daily); ↑-increased (4 MU three times daily);
↓-decreased (2 MU twice daily).
Eighteen cases (22%) met colistin AKI criteria, and these renal impairment cases were mostly
mild or moderate (i.e., increase in serum creatinine of up to 3-fold) and AKI was mostly observed in
patients with GFR of 50–129 mL/min prior to colistin therapy (10 cases of 18) with the median onset
(Q1; Q3) of AKI being 7.5 (4.5; 16) days. The median serum creatinine prior to colistin therapy, patient
age, cumulative colistin dose, and colistin over-dosing were not statistically significant risk factors of
colistin AKI. On the other hand, higher C-reactive protein (CRP) on the background was associated
with higher risk of colistin-induced AKI (Table 4). No patients with colistin AKI needed RRT.
Table 4. Association of different factors with colistin-induced acute kidney injury.
Parameter, Median (Q1; Q3) Patients withoutColistin AKI, n = 65
Patients with Colistin
AKI, n = 18
Statistical
Significance *
Age, years 63.0 (52.0; 74.0) 64.5 (61.0; 77.0) 0.169
Serum creatinine at the beginning of
colistin therapy, µmol/L 83.0 (54.0; 121.0) 82.0 (64.0; 146.0) 0.541
CRP at the beginning of colistin therapy 87.0 (66.0; 150.0) 164.0 (119.0; 182.0) 0.012
Cumulative colistin dose until outcome ** 72.0 (45.0; 141.0) 72.0 (48.0; 126.0) 0.578
* Mann-Whitney U Test. ** Outcome-stop of colistin, patient death, or colistin AKI. Abbreviations: AKI: acute
kidney injury; CRP: C-reactive protein.
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4. Discussion
Colistin has been used intravenously for many years as the optimal strategy for dosing, especially
in patients with renal impairment. Nevertheless, the research is unclear and varies among different
clinical settings and hospitals [13]. In addition, this study revealed a wide variety of colistin dosing in
patients with similar renal function. For example, patients with a GFR of 20–50 mL/min in the hospital
of study received a wide range of colistin doses daily (i.e., from 1 to 9 MU). Some patients in this study
received decreased LD of colistin or did not receive LD at all. Mostly, it was observed in the patient
group with decreased renal function or those on CRRT. However, a LD for colistin is usually always
recommended as it allows the patient to achieve a steady state of colistin much faster [14]. In addition,
in this study, a significant number of patients (43%) received colistin doses that were higher or lower
than is recommended in the SPC, especially patients with renal impairment. This wide variability
in colistin dosing could be explained by the lack of clear recommendations about dose adjustment
in the case of renal impairment during the years of the study. The advice from manufacturers about
colistin dose adjustment were more suitable for non-critically ill patients, and clinicians were guided
by different handbooks and articles that provide different recommendations [15]. For example, some
patients on RRT in one ICU within the study received an increased dose of colistin by 4.5 MU every 8 h.
This dosing regimen was based on the study results of Honore et al. regarding colistin adsorption on
some hemodialysis filters [10]. However, other ICU patents on RRT received a decreased colistin dose
rather than having it increased. In the previous year, the SPC of colistin was updated with information
about colistin dosing in critically ill patients with different renal functional states. This theoretically
could decrease the risk of over-dosing or under-dosing on colistin in this setting [9].
All possible types of kidney function were detected among patients in the study, ranging from
RRT to ARC. Assessment of renal function in critically ill patients is a major challenge, as the most
accurate methods for the detection of GFR (e.g., the use of exogenous filtration markers such as
radionuclide markers or iohexal) are usually not used in routine clinical practice [16]. Estimated GFR
based on serum creatinine level has a lot of limitations (e.g., it can be artificially increased in the case
of malnutrition). However, it still commonly guides the decisions of clinicians about dose adjustment
of the drug in real clinical situations.
In the SPC there are no specific recommendations for colistin dosing in the case of ARC.
However, the SPC suggest two possible daily doses (i.e., 9 and 12 MU daily), accompanied with
the comment that the safety of higher doses is not yet established [9]. Dalfino et al. suggest increased
colistin doses for patients with augmented clearance, such as 12 MU daily when creatinine clearance
(CrCl) >130 mL/min and 9 MU daily when CrCl is 60–130 mL/min [17]. Patients with ARC in this
study mostly received a standard colistin dose of 9 MU daily, but they had the tendency to receive
longer colistin therapy with a higher cumulative dose in comparison to other patient groups. However,
this difference did not reach statistical significance.
It is postulated that ARC could increase the clearance of many drugs. In case of continuous
infusions of sedatives or vasopressors, the dose could easily be adjusted according to clinical response.
However, the dose of antibiotics in this patient group is widely discussed in the literature, and no
indicator of decreased effectiveness is available. In addition, under-dosing could potentially lead
to therapy failure and the development of bacterial resistance [16]. It is still unknown if colistin
dose adjustment is needed in the case of ARC. When used for killing bacteria, colistin’s action is
concentration-dependent rather than time-dependent [18]. However, ARC mostly influences the
effectiveness of time-dependent renally cleared antibacterial drugs (e.g., beta-lactam antibiotics or
vancomycin) [19]. In the literature, there is not a lot of data about ARC’s role in colistin therapy.
There is information about other lipopolypeptide antibacterial agents with concentration-dependent
killing such as daptomycin, in which the pharmacokinetic ARC does not play an important role [5].
Nevertheless, patients with ARC have a lower incidence of AKI, and our study failed to prove a
protective role of ARC in the case of colistin AKI.
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In this study, colistin-induced kidney injury was detected in 22% of the cases with a median onset
of AKI of 7.5 days. Mostly, it was a first- or second-degree kidney injury. For example, this onset and
degree of colistin AKI, corresponds with a previously published Dalfino et al. study in which median
onset of colistin AKI was five days and in 42% of cases, colistin AKI was classified as first degree [17].
However, incidence of colistin-induced AKI among critically ill patients of different clinical setting
varied a lot, from 10–49% [7]. Hartzell et al. demonstrated that colistin-induced AKI is usually mild
and reversible [20]. In our study, no cases of permanent renal function loss or RRT due to colistin
therapy were detected. However, in many cases it was not possible to evaluate due to a high death
rate among the patients in the study. Generally, the incidence and severity of colistin AKI revealed in
this study corresponded with previously reported data.
Baseline renal impairment and older age were detected as colistin nephrotoxicity risk factors
in the study of Dalfino et al. [17]. However, this study did not show significant differences in the
parameters comparing patient groups with and without colistin-induced AKI. In addition, cumulative
colistin doses were not different among these two groups. This study revealed that higher baseline
CRP levels were associated with higher risk of colistin-induced nephrotoxicity. Previously, higher
CRP level has been reported as a risk factor for the development of radiocontrast media-induced AKI
in patients undergoing percutaneous coronary intervention [21]. However, we cannot exclude the
possibility that higher CRP was an indirect indicator of more severe comorbidities of the patients.
Further investigation of CRP level prior to colistin therapy as a possible risk marker of colistin AKI
could be beneficial.
If we take into account that the precise estimation of patient renal functional state is difficult
in the routine clinical practice of intensive care units, it is possible that the use of a standard dose
rather than an increased dose of colistin is safer in patients with renal hyperfiltration until TDM of
colistin is available. The use of TDM could theoretically be helpful for rational colistin dosing, as
some pharmacokinetic studies of colistin have already revealed inter-individual variations of colistin
concentration among critically ill patients on colistin therapy-for example, Karnik et al. found that
the concentration at steady state varied widely, from 0.1–2.0 mg/L [22]. Unfortunately, the target
concentration of colistin is not currently clear. Usually, target antibiotic concentrations should be
analyzed in the context of breakpoint MIC. For A. baumannii, the MIC50 is usually 0.5 mg/L and
the MIC90 is 2 mg/L. For P. aeruginosa, it is 2/2 mg/L, and for K. pneumoniae, it is 1/1.5 mg/L.
According to some study results, colistin nephrotoxicity could correlate with colistin concentration in
the higher blood concentration (2.5 mg/L). This is associated with higher AKI risk in comparison with
concentrations of 1.3–2.0 mg/L, but a possible target concentration of less than 2.5 mg/L is more likely
to produce bacteriostatic rather than bactericidal effect [13].
This study has several limitations, such as its retrospective design, heterogenicity of the study
population, difficulties in assessing patients’ renal functional state, and lack of information about
colistin concentrations in the blood. Nevertheless, it revealed challenges of colistin therapy in real
clinical situations. In addition, this study emphasized that the lack of clear recommendations from
the manufacturer could result in potentially inappropriate dosing and that TDM could be potentially
beneficial for some critically ill patients.
5. Conclusions
Colistin doses varied widely among patients, and dose adjustment was not TDM guided. In many
cases, colistin doses were lower or higher than is currently recommended, especially in patients
with renal impairment prior to colistin therapy. Colistin AKI risk was not correlated with serum
creatinine value prior to therapy or with the colistin cumulative dose, but rather correlated with
the CRP value at baseline. Patients with ARC received higher cumulative colistin doses and had a
tendency towards lower incidence of colistin AKI than patients with lower GFR on baseline. It is
important to evaluate the safety of higher colistin daily doses in patients with ARC in well-designed
studies before recommending its use in routine clinical practice.
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